


IBS Support with *L. rhamnosus* IDCC 3201

Clinically Studied Probiotic - *L. rhamnosus* IDCC 3201



Coated with  SHIELD technology for
enhanced stability and survivability



10B CFU/day



Lacticaseibacillus rhamnosus
IDCC 3201



Human Clinical Trial

Study Design

Randomized, double-blind, placebo-controlled

Subjects

30 adults with symptoms of IBS-C/Rome IV criteria

Dosage

L. rhamnosus IDCC 3201 at a dose of 10B CFU per day or placebo

Intake Period

8 weeks

Results


Improved symptoms of IBS-C



Improvement in QOL (quality-of-life)



Changes in fecal microbiota and fecal metabolome profiles



*Ref: Effect of *Lactoseibcillus rhamnosus* IDCC 3201 on irritable bowel syndrome with constipation: A randomized, double-blind, and placebo-controlled trial – Scientific Reports, 2024(E)

Possible Applications

